US20130041004A1 - Liquid Formulations Of Bendamustine - Google Patents

Liquid Formulations Of Bendamustine Download PDF

Info

Publication number
US20130041004A1
US20130041004A1 US13/655,498 US201213655498A US2013041004A1 US 20130041004 A1 US20130041004 A1 US 20130041004A1 US 201213655498 A US201213655498 A US 201213655498A US 2013041004 A1 US2013041004 A1 US 2013041004A1
Authority
US
United States
Prior art keywords
formulation
bendamustine
pharmaceutically acceptable
acceptable salt
dimethylacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/655,498
Inventor
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41559533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130041004(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/655,498 priority Critical patent/US20130041004A1/en
Publication of US20130041004A1 publication Critical patent/US20130041004A1/en
Priority to US14/084,768 priority patent/US20140080881A1/en
Priority to US14/151,242 priority patent/US20140128443A1/en
Priority to US14/221,422 priority patent/US20140206733A1/en
Priority to US14/814,570 priority patent/US20150335750A1/en
Priority to US15/688,182 priority patent/US20180125824A1/en
Priority to US16/835,562 priority patent/US20210008035A1/en
Priority to US17/015,175 priority patent/US20210113530A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to liquid formulations of bendamustine, and the pharmaceutical salts thereof.
  • bendamustine In light of its instability in aqueous solution, bendamustine is currently supplied as a lyophilized powder for injection. Just prior to its infusion, the medical practitioner reconstitutes the powder with Sterile Water for Injection. Reconstitution should yield a clear, colorless to pale yellow solution and the powder should completely dissolve in about 5 minutes. If particulate matter is observed, the reconstituted product should not be used and should be discarded. The reconstituted product is then transferred to a 0.9% Sodium Chloride Injection infusion bag within 30 minutes of reconstitution. This admixture should be a clear and colorless to slightly yellow solution. If the admixture comprises particulate matter or is discolored, it should be discarded and a fresh sample prepared.
  • the present invention is directed to liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, and a polar aprotic solvent.
  • Certain preferred embodiments include liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, a polar aprotic solvent, and a non-aqueous polar protic solvent.
  • FIG. 1 is a graph of a stability analysis of bendamustine in various solvents at 25° C.
  • FIG. 2 is a graph of a stability analysis of bendamustine in various solvents at 5° C.
  • FIG. 3 is a graph of bendamustine purity, over time, in 99% propylene glycol, at 5° C. and at 25° C.
  • pharmaceutically acceptable liquid formulations of bendamustine, and the pharmaceutically acceptable salts thereof, in particular the hydrochloride salt can be prepared by combining bendamustine, or the pharmaceutically acceptable salt thereof, with a polar aprotic solvent or mixture of polar aprotic solvents.
  • Polar, aprotic solvents are known in the art and include, for example, 1-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, dimethylacetamide, dimethyl sulfoxide, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethyl formamide, propylene carbonate.
  • polar, aprotic solvents are sufficiently non-nucleophilic towards bendamustine such that polar aprotic solvent-bendamustine adducts do not form over the course of typical commercial storage conditions.
  • Typical commercial storage conditions include time periods of, for example, about 30 days, about 90 days, about 180 days, and about 365 days (about 1 month, about 3 months, about 6 months, and about 1 year).
  • Typical commercial storage conditions also include temperatures of about 23° C. (ambient room temperature) and refrigerated temperatures below ambient room temperature, for example, about 5° C.
  • the liquid formulations of the present invention are stored at refrigerated temperatures.
  • nonaqueous polar protic solvents include alkyl alcohols, for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin, polysorbates, for example TWEEN 20, TWEEN 40, and TWEEN 80, and cyclodextrins (such as hydroxypropyl- ⁇ -cyclodextrin), polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol, and primary amides such as niacinamide.
  • alkyl alcohols for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin
  • polysorbates for example TWEEN 20, TWEEN 40, and TWEEN 80
  • cyclodextrins such as hydroxypropyl- ⁇ -cyclodextrin
  • polyalkylene glycols such as polyethylene glycol, polypropylene glycol, and polybutylene glycol
  • Such formulations will typically comprise 90% or less, by volume of the formulation, of the nonaqueous polar protic solvent. In other preferred embodiments, formulations will comprise between about 20% and about 85%, by volume of the formulation, of the nonaqueous polar protic solvent. In still other embodiments, formulations will comprise between about 30% and about 70%, by volume of the formulation, of the nonaqueous polar protic solvent. In most preferred embodiments, formulations will comprise about 80%, about 67% or about 34%, by volume of the formulation, of the nonaqueous polar protic solvent.
  • formulations of the present invention will comprise 10 moles per liter, or less, of the nonaqueous polar protic solvent.
  • formulations of the present invention will comprise between about 4 moles per liter to about 9.5 moles per liter, of the nonaqueous polar protic solvent.
  • formulations will comprise about 9.1 moles per liter of the nonaqueous polar protic solvent.
  • formulations will comprise about 4.6 moles per liter, of the nonaqueous polar protic solvent.
  • nonaqueous polar protic solvents are of sufficient nucleophilicity to form potentially undesirable polar protic solvent-bendamustine adducts, such adducts will not form during typical commercial storage if the concentration of the polar protic solvent is kept within the scope of the present invention.
  • Liquid formulations of the present invention are stable over the course of a typical commercial storage period.
  • “stable” is defined as no more than about a 10% loss of bendamustine under typical commercial storage conditions.
  • formulations of the present inventions will have no more than about a 10% loss of bendamustine, more preferably, no more than about a 5% loss of bendamustine, under typical commercial storage conditions.
  • Bendamustine converts to non-bendamustine products (i.e., “degrades”) upon exposure to certain nucleophiles, for example, water and alkyene glycols such as propylene glycol. Exposure of bendamustine to water can produce “HP1,” which is undesirable.
  • BM1 dimer Another undesirable compound that bendamustine can convert to over time is “BM1 dimer.”
  • DCE Still another undesirable compound that bendamustine can convert to over time is “DCE.”
  • esters of bendamustine can form, e.g., PG-1 and PG-2.
  • analysis of formulations of the present invention will exhibit 1.50% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. More preferably, the formulations will exhibit 1.0% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Even more preferably, the formulations will exhibit 0.5% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Most preferably, the formulations will exhibit about 0.1% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • analysis of the formulations will exhibit about 0.4% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • the formulations will exhibit about 0.10% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • analysis of the formulations will exhibit about 0.70% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • the formulations will exhibit about 0.30% or less of dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • the formulations will exhibit about 0.10% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • alkylene glycol as the nonaqueous polar protic solvent
  • analysis of those formulations will exhibit 1.5% or less of alkylene glycol esters of bendamustine, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • analysis of those formulations will exhibit 1.5% or less of propylene glycol esters PG-1 and PG-2, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • Analysis of the liquid formulations of the present invention can be performed using techniques known in the art, including, for example, HPLC, gas chromatography, and NMR. After exposure to typical commercial storage conditions, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to the storage conditions. Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to the storage conditions.
  • analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year).
  • analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
  • analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). More preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
  • Formulations of the present invention can comprise pharmaceutically useful concentrations of bendamustine, or a pharmaceutically acceptable salt thereof.
  • Useful concentrations include concentrations ranging from about 5 mg/mL to about 200 mg/mL.
  • the concentration of bendamustine, or a pharmaceutically acceptable salt thereof ranges from about 5 mg/mL to about 120 mg/mL.
  • Preferred concentrations include about 5 mg/mL, about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 100 mg/mL and about 200 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
  • Greater than 200 mg/ml of bendamustine, or a pharmaceutically acceptable salt thereof, for example, greater than about 300 mg/mL are also within the scope of the present invention, as are saturated solutions of bendamustine, or a pharmaceutically acceptable salt thereof.
  • the term “about” is defined as ⁇ 10%, preferably ⁇ 5%,
  • formulations of the present invention may further comprise other pharmaceutically acceptable excipients.
  • antioxidants e.g., tocopherol (Vitamin E), ascorbic acid, methyl paraben, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), and propyl gallate
  • surfactants e.g., polysorbates (TWEEN 20, TWEEN 40, TWEEN 80)
  • lipids e.g., dimyristoylphophatidylcholine (DMPC), Dimyristoylphosphatidylglycerol (DMPG), distearoylphophatidylglycerol (DSPG), fillers (e.g., mannitol), organic acids (e.g., citric acid, lactic acid, benzoic acid), hydrophilic polymers (e.g., polyethylene glycols (PEG 300, PEG 400), complexing agents (e.g., niacinamide, nicotinic acid
  • These methods comprise administering to the patient a therapeutically effective amount of a preparation prepared from a pharmaceutical formulation of the present invention.
  • therapeutically effective amount refers to the amount determined to be required to produce the physiological effect intended and associated with a given drug, as measured according to established pharmacokinetic methods and techniques, for the given administration route. Appropriate and specific therapeutically effective amounts can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques.
  • the effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
  • the liquid formulations of bendamustine described herein are intended to be administered via injection, for example, they may be administered subcutaneously, intracutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intralesionally, intracranially or via infusion.
  • the volume of the liquid formulation of the present invention needed for the required dose can be aseptically withdrawn and transferred to an infusion bag of 0.9% Sodium Chloride (or other pharmaceutically acceptable intravenous solution) for injection. After transfer, the contents of the infusion bag are thoroughly mixed.
  • Administration by intravenous infusion is typically provided over a time period of from about 30 to about 60 minutes.
  • Previously described lyophilized formulations of bendamustine required reconstitution of the lyophilized bendamustine prior to mixture with the acceptable intravenous solution before infusion.
  • the pharmaceutical formulations and preparations of the present invention can be administered in combination with one or more anti-neoplastic agents where the anti-neoplastic agent is given prior to, concurrently with, or subsequent to the administration of the formulation or preparation of the present invention.
  • Pharmaceutically acceptable anti-neoplastic agents are known in the art.
  • Preferred anti-neoplastic agents are those disclosed in co-pending U.S. application Ser. No. 11/330,868, filed Jan. 12, 2006, the entirety of which is incorporated herein by reference.
  • the three replicates were combined and mixed well and then pipetted into amber HPLC vials and placed in stability chambers at 25° C. and 5° C. All the samples were clear and colorless except for the DMI sample which was clear and yellow.
  • the 25° C. stability leveled out from about 180 days (about 6 months) to about 365 days (about 12 months, about 1 year). At 5° C., all solutions had a purity greater than 90%.
  • the analysis of stability samples can be seen in the graphs of FIGS. 1 and 2 .
  • bendamustine (BM1) in 99% propylene glycol degrades significantly when stored at 25° C. for less than 100 days. After storage at 5° C. for about 365 days, the purity of the bendamustine is about 80% or less.
  • TREANDA lyophilized mixture of bendamustine hydrochloride and mannitol; 25 mg (bendamustine hydrochloride) vials; 2) a 66% dimethylacetamide (DMA)/34% propylene glycol (PG) (w/w) solution (90 mg (bendamustine hydrochloride)/mL stock); and 3) a 100% DMA solution (45 mg (bendamustine hydrochloride)/mL stock).
  • DMA dimethylacetamide
  • PG propylene glycol
  • the resulting solutions were administered as a bolus via a saphenous vein at a fixed volume of 1.0 mL/kg. There was at least a 7-day washout period separating successive doses.
  • blood samples for pharmacokinetic profiling of bendamustine and its 2 active circulating metabolites, ⁇ -hydroxybendamustine (M3) and N-des-methylbendamustine (M4) were collected via a femoral vein immediately prior to dosing and at preselected timepoints through 12 hr postdose.
  • Concentrations of bendamustine, M3 and M4 in plasma samples were determined using a validated high-performance liquid chromatography method with tandem mass spectrometric detection (LC-MS/MS) as follows. Bendamustine and the M3 and M4 metabolites are extracted from plasma by protein precipitation using acetonitrile. After the extraction, the aliquoted sample is acidified with 1% formic acid and bendamustine with an added carbon in the carboxylic acid chain is added as an internal standard. The samples are evaporated to dryness and the residue is reconstituted with an acetonitrile/water/formic acid/ammonium formate mixture.
  • LC-MS/MS tandem mass spectrometric detection
  • the sample is injected into an HPLC system with LC/MS/MS detection using a Phenomenex Synergi Max-RP column with an acetonitrile/water/formic acid/ammonium formate mobile phase.
  • Pharmacokinetic analyses were performed using noncompartmental methods.
  • C max and AUC bendamustine systemic exposure
  • the respective mean values of C max and AUC 0- ⁇ for bendamustine were 6037 ng/mL and 2314 ng ⁇ hr/mL for the TREANDA formulation, 7380 ng/mL and 2854 ng ⁇ hr/mL for the 66% DMA/34% PG formulation and 6209 ng/mL and 2372 ng ⁇ hr/mL for the 100% DMA formulation.
  • Plasma clearance (CL) and volume of distribution (V z and V ss ) for bendamustine were also comparable between each of the 3 formulations (See Table III).
  • t max , hr is given as Median [range]
  • t 1/2 is given as the Harmonic Mean
  • ⁇ z is the slope of line in elimination phase used to calculate half-life
  • MRT 0- ⁇ is the mean residence time.
  • Admixtures in 0.9% sodium chloride 500 mL bag were prepared at a high dose (360 mg bendamustine hydrochloride) and purity was determined over time at room temperature for up to 8 hours using HPLC, using a Zorbax Bonus-RP column with a gradient from 93% 0.1% trifluoroacetic acid in water (Mobile Phase A)/7% 0.1% trifluoroacetic acid in acetonitrile (Mobile Phase B) to 10% Mobile Phase A/90% Mobile Phase B.
  • the 66% DMA/34% PG formulation had a concentration of bendamustine hydrochloride of 90 mg/g, so 4 mL was injected into a 500 mL bag of saline, inverted 10 times and sampled at room temperature for 8 hours. After 8 hours the purity was 95.4%. This is within the label requirements for dosing Treanda.
  • This formulation of the present invention could be used for up to 8 hours at room temperature.
  • reconstituted Treanda can only be stored at room temperature for up to 3 hours.
  • the 100% DMA formulation had a concentration of 45 mg/g, so 8 mL was injected into a 500 mL bag of saline, inverted 10 times, and sampled at room temperature for 4 hours. After 4 hours the purity was 97.9%. This formulation of the present invention could be used for more than 4 hours at room temperature.
  • the comparative Treanda admixture purity was 95.0% after 4 hours at 25° C.

Abstract

Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 13/362,430, filed Jan. 31, 2012, which is a continuation of U.S. application Ser. No. 13/048,325, filed Mar. 15, 2011, now abandoned, which is a continuation of International Application No. PCT/US2009/58023, filed Sep. 23, 2009, which claims the benefit of U.S. Provisional Application No. 61/100,074, filed Sep. 25, 2008, the entireties of which are incorporated by reference herein.
  • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to liquid formulations of bendamustine, and the pharmaceutical salts thereof.
  • BACKGROUND OF THE INVENTION
  • Bendamustine, (4-{5-[bis(2-chloroethyl)amino]-1-methyl-2-benzimidazolyl}butyric acid
  • Figure US20130041004A1-20130214-C00001
  • is an atypical structure with a benzimidazole ring, which structure includes an active nitrogen mustard. Bendamustine was initially synthesized in 1963 in the German Democratic Republic and was available from 1971 to 1992 in that location under the name Cytostasan®. Since that time, it has been marketed in Germany under the tradename Ribomustin®. It is currently available for use in the United States under the tradename Treanda® (Cephalon, Inc., Frazer, Pa.). It has been widely used to treat chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, and breast cancer.
  • Like other nitrogen mustards, bendamustine hydrolyzes in aqueous solution, with the major degradant being the primary alcohol HP1 (See U.S. application Ser. No. 11/330,868, the entirety of which is incorporated herein):
  • Figure US20130041004A1-20130214-C00002
  • In light of its instability in aqueous solution, bendamustine is currently supplied as a lyophilized powder for injection. Just prior to its infusion, the medical practitioner reconstitutes the powder with Sterile Water for Injection. Reconstitution should yield a clear, colorless to pale yellow solution and the powder should completely dissolve in about 5 minutes. If particulate matter is observed, the reconstituted product should not be used and should be discarded. The reconstituted product is then transferred to a 0.9% Sodium Chloride Injection infusion bag within 30 minutes of reconstitution. This admixture should be a clear and colorless to slightly yellow solution. If the admixture comprises particulate matter or is discolored, it should be discarded and a fresh sample prepared.
  • The reconstitution of the bendamustine lyophilized powder is time consuming and cumbersome. Moreover, lyophilization of solids on a commercial scale requires specialized equipment and incurs significant expense. As such, formulations of bendamustine that do not require lyophilization and/or reconstitution are needed.
  • Solutions of bendamustine hydrochloride in anhydrous propylene glycol, prepared under an inert gas atmosphere, have been reported (GDR Patent 159289). It was reported that analysis of these solutions using thin-layer chromatography, eluting with butanol/acetic acid/water (4:1:5) and detection with Dragendorff reagent and UV (360 nm) did not suggest any decomposition. Curiously, however, commercial development of propylene glycol formulations have heretofore not been reported. Thus, improved liquid formulations of bendamustine are still needed.
  • SUMMARY OF THE INVENTION
  • The present invention is directed to liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, and a polar aprotic solvent. Certain preferred embodiments include liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, a polar aprotic solvent, and a non-aqueous polar protic solvent. Methods of making and using the formulations of the present invention are also described, as are methods of treating cancer using the claimed formulations.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph of a stability analysis of bendamustine in various solvents at 25° C.
  • FIG. 2 is a graph of a stability analysis of bendamustine in various solvents at 5° C.
  • FIG. 3 is a graph of bendamustine purity, over time, in 99% propylene glycol, at 5° C. and at 25° C.
  • FIG. 4 shows the mean+standard deviation concentration-versus-time profiles of bendamustine in male Cynomolgus monkeys (N=4) administered single 3 mg/kg bolus intravenous doses of bendamustine hydrochloride in 3 different formulations.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Stable, liquid formulations of bendamustine have been discovered and are reported herein.
  • Experiments to produce commercially viable propylene glycol preparations have been performed. Unfortunately, the results described in GDR Patent 159289 were not reproducible. Solutions of bendamustine in 99% propylene glycol degraded to non-bendamustine products over a time equivalent to commercial storage. Two of the impurities were identified as propylene glycol esters of bendamustine. As such, a 100% propylene glycol commercial formulation of bendamustine is not feasible for pharmaceutical purposes.
  • It has been determined that pharmaceutically acceptable liquid formulations of bendamustine, and the pharmaceutically acceptable salts thereof, in particular the hydrochloride salt, can be prepared by combining bendamustine, or the pharmaceutically acceptable salt thereof, with a polar aprotic solvent or mixture of polar aprotic solvents. Polar, aprotic solvents are known in the art and include, for example, 1-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, dimethylacetamide, dimethyl sulfoxide, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethyl formamide, propylene carbonate. See also, e.g., Florence Mottu, et al. Organic solvents for pharmaceutical parenterals and embolic liquids: A review of toxicity data, PDA J. Pharma. Sci. & Tech. vol 54, no. 6, 456-469 (November-December 2000). Particularly preferred polar aprotic solvents include dimethylacetamide, dimethyl sulfoxide, and mixtures thereof.
  • Without wishing to be held to any particular theory, it is believed that polar, aprotic solvents are sufficiently non-nucleophilic towards bendamustine such that polar aprotic solvent-bendamustine adducts do not form over the course of typical commercial storage conditions. Typical commercial storage conditions include time periods of, for example, about 30 days, about 90 days, about 180 days, and about 365 days (about 1 month, about 3 months, about 6 months, and about 1 year). Typical commercial storage conditions also include temperatures of about 23° C. (ambient room temperature) and refrigerated temperatures below ambient room temperature, for example, about 5° C. Preferably, the liquid formulations of the present invention are stored at refrigerated temperatures.
  • It has also been discovered that stable formulations of bendamustine can be obtained by mixing a polar aprotic solvent, or a mixture of polar aprotic solvents, with a non-aqueous polar protic solvent or mixture of nonaqueous polar protic solvents. Pharmaceutically acceptable nonaqueous polar protic solvents are known in the art and include alkyl alcohols, for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin, polysorbates, for example TWEEN 20, TWEEN 40, and TWEEN 80, and cyclodextrins (such as hydroxypropyl-β-cyclodextrin), polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol, and primary amides such as niacinamide.
  • Such formulations will typically comprise 90% or less, by volume of the formulation, of the nonaqueous polar protic solvent. In other preferred embodiments, formulations will comprise between about 20% and about 85%, by volume of the formulation, of the nonaqueous polar protic solvent. In still other embodiments, formulations will comprise between about 30% and about 70%, by volume of the formulation, of the nonaqueous polar protic solvent. In most preferred embodiments, formulations will comprise about 80%, about 67% or about 34%, by volume of the formulation, of the nonaqueous polar protic solvent.
  • Alternatively, formulations of the present invention will comprise 10 moles per liter, or less, of the nonaqueous polar protic solvent. Preferably, formulations of the present invention will comprise between about 4 moles per liter to about 9.5 moles per liter, of the nonaqueous polar protic solvent. In certain embodiments, formulations will comprise about 9.1 moles per liter of the nonaqueous polar protic solvent. In other embodiments, formulations will comprise about 4.6 moles per liter, of the nonaqueous polar protic solvent.
  • While not wishing to be held to any particular theory, it is believed that while nonaqueous polar protic solvents are of sufficient nucleophilicity to form potentially undesirable polar protic solvent-bendamustine adducts, such adducts will not form during typical commercial storage if the concentration of the polar protic solvent is kept within the scope of the present invention.
  • Liquid formulations of the present invention are stable over the course of a typical commercial storage period. As used herein, “stable” is defined as no more than about a 10% loss of bendamustine under typical commercial storage conditions. Preferably, formulations of the present inventions will have no more than about a 10% loss of bendamustine, more preferably, no more than about a 5% loss of bendamustine, under typical commercial storage conditions.
  • Bendamustine converts to non-bendamustine products (i.e., “degrades”) upon exposure to certain nucleophiles, for example, water and alkyene glycols such as propylene glycol. Exposure of bendamustine to water can produce “HP1,” which is undesirable.
  • Figure US20130041004A1-20130214-C00003
  • Another undesirable compound that bendamustine can convert to over time is “BM1 dimer.”
  • Figure US20130041004A1-20130214-C00004
  • Still another undesirable compound that bendamustine can convert to over time is “DCE.”
  • Figure US20130041004A1-20130214-C00005
  • Upon exposure to an alkylene glycol, for example, propylene glycol, esters of bendamustine can form, e.g., PG-1 and PG-2.
  • Figure US20130041004A1-20130214-C00006
  • In preferred embodiments of the present invention, analysis of formulations of the present invention will exhibit 1.50% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. More preferably, the formulations will exhibit 1.0% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Even more preferably, the formulations will exhibit 0.5% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Most preferably, the formulations will exhibit about 0.1% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • In other embodiments of the present invention, analysis of the formulations will exhibit about 0.4% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Preferably, the formulations will exhibit about 0.10% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • In certain other embodiments of the present invention, analysis of the formulations will exhibit about 0.70% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Preferably, the formulations will exhibit about 0.30% or less of dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. In most preferred embodiments, the formulations will exhibit about 0.10% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • In those embodiments of the present invention comprising alkylene glycol as the nonaqueous polar protic solvent, analysis of those formulations will exhibit 1.5% or less of alkylene glycol esters of bendamustine, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. For example, in those embodiments comprising propylene glycol, analysis of those formulations will exhibit 1.5% or less of propylene glycol esters PG-1 and PG-2, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
  • Analysis of the liquid formulations of the present invention can be performed using techniques known in the art, including, for example, HPLC, gas chromatography, and NMR. After exposure to typical commercial storage conditions, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to the storage conditions. Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to the storage conditions.
  • In preferred embodiments of the present invention, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). Preferably, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months). Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). More preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
  • Formulations of the present invention can comprise pharmaceutically useful concentrations of bendamustine, or a pharmaceutically acceptable salt thereof. Useful concentrations include concentrations ranging from about 5 mg/mL to about 200 mg/mL. Preferably, the concentration of bendamustine, or a pharmaceutically acceptable salt thereof, ranges from about 5 mg/mL to about 120 mg/mL. Preferred concentrations include about 5 mg/mL, about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 100 mg/mL and about 200 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof. Greater than 200 mg/ml of bendamustine, or a pharmaceutically acceptable salt thereof, for example, greater than about 300 mg/mL, are also within the scope of the present invention, as are saturated solutions of bendamustine, or a pharmaceutically acceptable salt thereof.
  • As used herein, the term “about” is defined as ±10%, preferably ±5%,
  • In addition to comprising a polar aprotic solvent, or mixture of polar aprotic solvents, and optionally, a nonaqueous polar protic solvent, or mixture of solvents, formulations of the present invention may further comprise other pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients are known in the art and include, for example, antioxidants (e.g., tocopherol (Vitamin E), ascorbic acid, methyl paraben, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), and propyl gallate), surfactants, (e.g., polysorbates (TWEEN 20, TWEEN 40, TWEEN 80)), lipids (e.g., dimyristoylphophatidylcholine (DMPC), Dimyristoylphosphatidylglycerol (DMPG), distearoylphophatidylglycerol (DSPG), fillers (e.g., mannitol), organic acids (e.g., citric acid, lactic acid, benzoic acid), hydrophilic polymers (e.g., polyethylene glycols (PEG 300, PEG 400), complexing agents (e.g., niacinamide, nicotinic acid, creatine, cyclodextrins), and preservatives (e.g., benzyl alcohol).
  • Also within the scope of the invention are methods of treating diseases, such as, for example, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or breast cancer, with a pharmaceutical formulation of the present invention. These methods comprise administering to the patient a therapeutically effective amount of a preparation prepared from a pharmaceutical formulation of the present invention. The term “therapeutically effective amount,” as used herein, refers to the amount determined to be required to produce the physiological effect intended and associated with a given drug, as measured according to established pharmacokinetic methods and techniques, for the given administration route. Appropriate and specific therapeutically effective amounts can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques. The effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
  • The liquid formulations of bendamustine described herein are intended to be administered via injection, for example, they may be administered subcutaneously, intracutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intralesionally, intracranially or via infusion. In a typical preparation, the volume of the liquid formulation of the present invention needed for the required dose can be aseptically withdrawn and transferred to an infusion bag of 0.9% Sodium Chloride (or other pharmaceutically acceptable intravenous solution) for injection. After transfer, the contents of the infusion bag are thoroughly mixed. Administration by intravenous infusion is typically provided over a time period of from about 30 to about 60 minutes. Previously described lyophilized formulations of bendamustine required reconstitution of the lyophilized bendamustine prior to mixture with the acceptable intravenous solution before infusion.
  • It is envisioned that the pharmaceutical formulations and preparations of the present invention can be administered in combination with one or more anti-neoplastic agents where the anti-neoplastic agent is given prior to, concurrently with, or subsequent to the administration of the formulation or preparation of the present invention. Pharmaceutically acceptable anti-neoplastic agents are known in the art. Preferred anti-neoplastic agents are those disclosed in co-pending U.S. application Ser. No. 11/330,868, filed Jan. 12, 2006, the entirety of which is incorporated herein by reference.
  • EXAMPLES Solubility and Stability of Bendamustine Hydrochloride in Polar Aprotic Solvents
  • Equilibrium solubility was determined for solvents including 1-methyl-2-pyrrolidone (NMP), 1,3-dimethyl-2-imidazolidinone (DMI), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), acetone, tetrahydrofuran (THF), dimethylformamide (DMF), and propylene carbonate (PC). The solubility of bendamustine hydrochloride was also determined for two solutions, 25 mg/mL niacinamide in DMA and 66% DMA/34% propylene glycol (PG). A saturated solution of bendamustine hydrochloride was made in triplicate for each solvent or solution and mixed on a Lab-Quake with gentle mixing and low shear for 3 days at room temperature. A sample of each suspension was put into a microcentrifuge tube and spun at 10,000 rpm for 5 min on an Eppendorf microcentrifuge. The supernatant was removed and put into a clean vial. Each solution was diluted with sample solvent: 50% NMP/50% 0.1% trifluoroacetic acid in water. A reverse phase method for bendamustine hydrochloride was used to determine the concentration of each sample calculated from a standard. Analysis was performed within 18 hours of preparation of the diluted sample. The solubilities are listed in Table I below. Each value is an average of three samples.
  • TABLE I
    Sample* % Purity Assay (mg/mL)
    NMP 99.1 104.0
    DMI 98.5 75.8
    DMSO 99.5 311.7
    DMF 99.6 71.8
    66% DMA/34% PG 99.5 110.1
    DMA 99.4 56.2
    PC 98.7 7.7
    Niacinamide/DMA 99.2 61.3
    *acetone and THF have no measurable solubility of bendamustine.
  • The three replicates were combined and mixed well and then pipetted into amber HPLC vials and placed in stability chambers at 25° C. and 5° C. All the samples were clear and colorless except for the DMI sample which was clear and yellow. The 25° C. stability leveled out from about 180 days (about 6 months) to about 365 days (about 12 months, about 1 year). At 5° C., all solutions had a purity greater than 90%. The analysis of stability samples can be seen in the graphs of FIGS. 1 and 2.
  • TABLE II
    Impurity profile of certain liquid formulations of Bendamustine
    HCl after storage at 5° C. for about 12 months
    BM1
    DCE HP1 dimer PG-1 PG-2
    Formulation (Area %) (Area %) (Area %) (Area %) (Area %)
    Niacinamide/ 1.40 0.08 0.06 ND ND
    DMA
    DMA 1.10 0.08 0.05 ND ND
    66% DMA/ 0.12 0.08 0.06 1.09 0.27
    34% PG
    DMF 0.07 0.11 0.07 ND ND
    NMP 0.90 0.10 ND ND ND
    DMSO 0.04 0.38 0.70 ND ND
    ND = not detected

    Analysis conducted using reverse phase HPLC with 50% NMP/50% 0.1% trifluoroacetic acid in water as the running solvent.
  • As can be seen in FIG. 3, bendamustine (BM1) in 99% propylene glycol degrades significantly when stored at 25° C. for less than 100 days. After storage at 5° C. for about 365 days, the purity of the bendamustine is about 80% or less.
  • Pharmacokinetic Study of Formulations in Monkey
  • 4 fasted (18 to 23 hr), drug-naive male cynomolgus monkeys consecutively received single 3-mg/kg bolus intravenous doses of bendamustine hydrochloride prepared from 3 different formulations. The formulations evaluated in the study included:
  • 1) TREANDA (lyophilized mixture of bendamustine hydrochloride and mannitol; 25 mg (bendamustine hydrochloride) vials; 2) a 66% dimethylacetamide (DMA)/34% propylene glycol (PG) (w/w) solution (90 mg (bendamustine hydrochloride)/mL stock); and 3) a 100% DMA solution (45 mg (bendamustine hydrochloride)/mL stock). The lyophilized powder and stock solutions of bendamustine hydrochloride were constituted or diluted with 0.9% saline, as appropriate, to give solutions of 3 mg bendamustine hydrochloride/ml, just prior to dose administration. The resulting solutions were administered as a bolus via a saphenous vein at a fixed volume of 1.0 mL/kg. There was at least a 7-day washout period separating successive doses. During all 3 phases of dosing, blood samples for pharmacokinetic profiling of bendamustine and its 2 active circulating metabolites, γ-hydroxybendamustine (M3) and N-des-methylbendamustine (M4), were collected via a femoral vein immediately prior to dosing and at preselected timepoints through 12 hr postdose. Concentrations of bendamustine, M3 and M4 in plasma samples were determined using a validated high-performance liquid chromatography method with tandem mass spectrometric detection (LC-MS/MS) as follows. Bendamustine and the M3 and M4 metabolites are extracted from plasma by protein precipitation using acetonitrile. After the extraction, the aliquoted sample is acidified with 1% formic acid and bendamustine with an added carbon in the carboxylic acid chain is added as an internal standard. The samples are evaporated to dryness and the residue is reconstituted with an acetonitrile/water/formic acid/ammonium formate mixture. The sample is injected into an HPLC system with LC/MS/MS detection using a Phenomenex Synergi Max-RP column with an acetonitrile/water/formic acid/ammonium formate mobile phase. Pharmacokinetic analyses were performed using noncompartmental methods.
  • After single bolus intravenous doses of bendamustine hydrochloride to male cynomolgus monkeys, the shapes of the mean plasma concentration-versus-time profiles of bendamustine were similar in each of the 3 formulations (See FIG. 4). In all cases, the highest observed plasma levels of bendamustine were achieved at 0.083 hr postdose (ie, the first sampling time after dose administration) and subsequent removal of the compound from plasma occurred in a bi-phasic manner that was characterized by an initial rapid distribution phase and a somewhat slower terminal phase of drug elimination. The harmonic mean t1/2 of the terminal phase was approximately 0.6 hr for each formulation (See Table III).
  • In addition to the similarities in the shapes of the mean plasma concentration-versus-time profiles, the 3 formulations were also similar with respect to bendamustine systemic exposure (i.e., Cmax and AUC). Specifically, the respective mean values of Cmax and AUC0-∞ for bendamustine were 6037 ng/mL and 2314 ng·hr/mL for the TREANDA formulation, 7380 ng/mL and 2854 ng·hr/mL for the 66% DMA/34% PG formulation and 6209 ng/mL and 2372 ng·hr/mL for the 100% DMA formulation. Plasma clearance (CL) and volume of distribution (Vz and Vss) for bendamustine were also comparable between each of the 3 formulations (See Table III). In Table III, tmax, hr is given as Median [range], t1/2, hr is given as the Harmonic Mean, λz, hr−1 is the slope of line in elimination phase used to calculate half-life, and MRT0-∞ is the mean residence time.
  • In summary, the pharmacokinetic profiles of bendamustine, M3 and M4 for the 2 liquid formulations of bendamustine hydrochloride were qualitatively and quantitatively similar to those obtained for the TREANDA formulation after single bolus intravenous doses to monkeys.
  • Table III shows the mean+/−Standard Deviation pharmacokinetic parameters of bendamustine in male Cynomolgus monkeys (N=4) administered single 3 mg/kg bolus intravenous doses of bendamustine hydrochloride in the three different formulations.
  • TABLE III
    Formulation
    Parameter TREANDA 66% DMA/34% PG 100% DMA
    C0, ng/mL  8664 ± 3841   10716 ± 2033   8956 ± 1965 
    Cmax, ng/mL  6037 ± 2456    7380 ± 1170   6209 ± 1300 
    tmax, hr 0.083 0.083 0.083
    [0.083 for all] [0.083 for all] [0.083 for all]
    AUC0−t, ng•hr/mL  2313 ± 800     2853 ± 398    2371 ± 535  
    AUC0−∞, ng•hr/mL  2314 ± 800     2854 ± 398    2372 ± 535  
    λz, hr−1 1.220 ± 0.111  1.295 ± 0.108 1.092 ± 0.219
    t1/2, hr 0.57 0.54 0.63
    CL, L/hr/kg  1.27 ± 0.40   0.96 ± 0.14   1.18 ± 0.27 
    Vz, L/kg  1.04 ± 0.36   0.74 ± 0.05   1.17 ± 0.44 
    Vss, L/kg  0.34 ± 0.11   0.26 ± 0.05   0.30 ± 0.04 
    MRT0−∞, hr  0.26 ± 0.02   0.27 ± 0.02   0.26 ± 0.03 
  • In-Use Studies of Formulations
  • Admixtures in 0.9% sodium chloride (500 mL bag) were prepared at a high dose (360 mg bendamustine hydrochloride) and purity was determined over time at room temperature for up to 8 hours using HPLC, using a Zorbax Bonus-RP column with a gradient from 93% 0.1% trifluoroacetic acid in water (Mobile Phase A)/7% 0.1% trifluoroacetic acid in acetonitrile (Mobile Phase B) to 10% Mobile Phase A/90% Mobile Phase B.
  • The 66% DMA/34% PG formulation had a concentration of bendamustine hydrochloride of 90 mg/g, so 4 mL was injected into a 500 mL bag of saline, inverted 10 times and sampled at room temperature for 8 hours. After 8 hours the purity was 95.4%. This is within the label requirements for dosing Treanda. This formulation of the present invention could be used for up to 8 hours at room temperature. By way of contrast, reconstituted Treanda can only be stored at room temperature for up to 3 hours.
  • The 100% DMA formulation had a concentration of 45 mg/g, so 8 mL was injected into a 500 mL bag of saline, inverted 10 times, and sampled at room temperature for 4 hours. After 4 hours the purity was 97.9%. This formulation of the present invention could be used for more than 4 hours at room temperature.
  • The comparative Treanda admixture purity was 95.0% after 4 hours at 25° C.
  • As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in view of the above teachings. It is therefore understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.

Claims (30)

1. A stable, liquid, pharmaceutical formulation comprising bendamustine, or a pharmaceutically acceptable salt thereof, and a polar aprotic solvent, wherein said formulation is suitable for injection into a patient following dilution with a pharmaceutically acceptable diluent.
2. The formulation of claim 1, wherein the polar aprotic solvent is 1-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, dimethylacetamide, dimethyl sulfoxide, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethyl formamide, propylene carbonate, or a mixture thereof.
3. The formulation of claim 2, wherein the polar aprotic solvent is dimethylacetamide.
4. The formulation of claim 1, further comprising a non-aqueous polar protic solvent.
5. The formulation of claim 4, comprising between about 30% and about 70%, by volume of the formulation, of the nonaqueous polar protic solvent.
6. The formulation of claim 4, wherein the non-aqueous polar protic solvent is an alcohol, a polyalkylene glycol, an amide, or a mixture thereof.
7. The formulation of claim 4, wherein the non-aqueous polar protic solvent is an alcohol.
8. The formulation of claim 7, wherein the alcohol is a cyclodextrin.
9. The formulation of claim 4, wherein the non-aqueous polar protic solvent is propylene glycol.
10. The formulation of claim 4, wherein the polar aprotic solvent is dimethylacetamide.
11. The formulation of claim 10, wherein the nonaqueous polar protic solvent is propylene glycol.
12. The formulation of claim 11, comprising about 66% (v/v) of the dimethylacetamide and about 34% (v/v) of the propylene glycol.
13. The formulation of claim 12, comprising from about 5 mg/ml to about 120 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
14. The formulation of claim 13, comprising about 100 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
15. The formulation of claim 1, comprising from about 5 mg/ml to about 200 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
16. The formulation of claim 1, comprising from about 5 mg/ml to about 120 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
17. The formulation of claim 1, comprising about 100 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
18. The formulation of claim 1, wherein the bendamustine is bendamustine hydrochloride.
19. The formulation of claim 1, further comprising at least one pharmaceutically acceptable excipient or diluent.
20. The formulation of claim 4, further comprising at least one pharmaceutically acceptable excipient or diluent.
21. The formulation of claim 1, further comprising an antioxidant, a surfactant, a lipid, a filler, an organic acid, a hydrophilic polymer, a complexing agent, a preservative, or a combination thereof.
22. A method of treating cancer comprising
providing a liquid, pharmaceutical formulation of claim 1;
diluting the liquid pharmaceutical formulation with a pharmaceutically acceptable injectable diluent to form an injectable pharmaceutical preparation;
administering the injectable pharmaceutical preparation to a patient in need of treatment for cancer.
23. The method of claim 22, wherein the liquid pharmaceutical formulation comprises the polar aprotic solvent dimethylacetamide.
24. The method of claim 23, wherein the liquid pharmaceutical formulation comprises the polar aprotic solvent dimethylacetamide and further comprises the nonaqueous polar protic solvent propylene glycol
25. The method of claim 24, wherein the liquid pharmaceutical formulation comprises about 66% (v/v) of the dimethylacetamide and about 34% (v/v) of the propylene glycol.
26. The method of claim 25, wherein the liquid pharmaceutical formulation comprises from about 5 mg/ml to about 120 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
27. The method of claim 26, wherein the liquid pharmaceutical formulation comprises about 100 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
28. The method of claim 22, wherein the pharmaceutically acceptable injectable diluent is 0.9% sodium chloride.
29. The method of claim 22, wherein the cancer is chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or breast cancer.
30. The method of claim 29, wherein the cancer is chronic lymphocytic leukemia or non-Hodgkin's lymphoma.
US13/655,498 2008-09-25 2012-10-19 Liquid Formulations Of Bendamustine Abandoned US20130041004A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US13/655,498 US20130041004A1 (en) 2008-09-25 2012-10-19 Liquid Formulations Of Bendamustine
US14/084,768 US20140080881A1 (en) 2008-09-25 2013-11-20 Liquid Formulations of Bendamustine
US14/151,242 US20140128443A1 (en) 2008-09-25 2014-01-09 Liquid Formulations Of Bendamustine
US14/221,422 US20140206733A1 (en) 2008-09-25 2014-03-21 Liquid Formulations Of Bendamustine
US14/814,570 US20150335750A1 (en) 2008-09-25 2015-07-31 Liquid Formulations of Bendamustine
US15/688,182 US20180125824A1 (en) 2008-09-25 2017-08-28 Liquid formulations of bendamustine
US16/835,562 US20210008035A1 (en) 2008-09-25 2020-03-31 Liquid formulations of bendamustine
US17/015,175 US20210113530A1 (en) 2008-09-25 2020-09-09 Liquid formulations of bendamustine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10007408P 2008-09-25 2008-09-25
PCT/US2009/058023 WO2010036702A1 (en) 2008-09-25 2009-09-23 Liquid formulations of bendamustine
US13/048,325 US20110190363A1 (en) 2008-09-25 2011-03-15 Liquid formulations of bendamustine
US13/362,430 US8344006B2 (en) 2008-09-25 2012-01-31 Liquid formulations of bendamustine
US13/655,498 US20130041004A1 (en) 2008-09-25 2012-10-19 Liquid Formulations Of Bendamustine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/362,430 Continuation US8344006B2 (en) 2008-09-25 2012-01-31 Liquid formulations of bendamustine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/084,768 Division US20140080881A1 (en) 2008-09-25 2013-11-20 Liquid Formulations of Bendamustine
US14/151,242 Continuation US20140128443A1 (en) 2008-09-25 2014-01-09 Liquid Formulations Of Bendamustine

Publications (1)

Publication Number Publication Date
US20130041004A1 true US20130041004A1 (en) 2013-02-14

Family

ID=41559533

Family Applications (10)

Application Number Title Priority Date Filing Date
US13/048,325 Abandoned US20110190363A1 (en) 2008-09-25 2011-03-15 Liquid formulations of bendamustine
US13/362,430 Active US8344006B2 (en) 2008-09-25 2012-01-31 Liquid formulations of bendamustine
US13/655,498 Abandoned US20130041004A1 (en) 2008-09-25 2012-10-19 Liquid Formulations Of Bendamustine
US14/084,768 Abandoned US20140080881A1 (en) 2008-09-25 2013-11-20 Liquid Formulations of Bendamustine
US14/151,242 Abandoned US20140128443A1 (en) 2008-09-25 2014-01-09 Liquid Formulations Of Bendamustine
US14/221,422 Abandoned US20140206733A1 (en) 2008-09-25 2014-03-21 Liquid Formulations Of Bendamustine
US14/814,570 Abandoned US20150335750A1 (en) 2008-09-25 2015-07-31 Liquid Formulations of Bendamustine
US15/688,182 Abandoned US20180125824A1 (en) 2008-09-25 2017-08-28 Liquid formulations of bendamustine
US16/835,562 Abandoned US20210008035A1 (en) 2008-09-25 2020-03-31 Liquid formulations of bendamustine
US17/015,175 Abandoned US20210113530A1 (en) 2008-09-25 2020-09-09 Liquid formulations of bendamustine

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/048,325 Abandoned US20110190363A1 (en) 2008-09-25 2011-03-15 Liquid formulations of bendamustine
US13/362,430 Active US8344006B2 (en) 2008-09-25 2012-01-31 Liquid formulations of bendamustine

Family Applications After (7)

Application Number Title Priority Date Filing Date
US14/084,768 Abandoned US20140080881A1 (en) 2008-09-25 2013-11-20 Liquid Formulations of Bendamustine
US14/151,242 Abandoned US20140128443A1 (en) 2008-09-25 2014-01-09 Liquid Formulations Of Bendamustine
US14/221,422 Abandoned US20140206733A1 (en) 2008-09-25 2014-03-21 Liquid Formulations Of Bendamustine
US14/814,570 Abandoned US20150335750A1 (en) 2008-09-25 2015-07-31 Liquid Formulations of Bendamustine
US15/688,182 Abandoned US20180125824A1 (en) 2008-09-25 2017-08-28 Liquid formulations of bendamustine
US16/835,562 Abandoned US20210008035A1 (en) 2008-09-25 2020-03-31 Liquid formulations of bendamustine
US17/015,175 Abandoned US20210113530A1 (en) 2008-09-25 2020-09-09 Liquid formulations of bendamustine

Country Status (9)

Country Link
US (10) US20110190363A1 (en)
EP (2) EP2326306A1 (en)
JP (1) JP5670335B2 (en)
CN (2) CN104224703A (en)
AU (5) AU2009296734B2 (en)
CA (1) CA2735899A1 (en)
HK (1) HK1211462A1 (en)
MX (1) MX2011002936A (en)
WO (1) WO2010036702A1 (en)

Cited By (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20100203096A1 (en) * 2009-02-06 2010-08-12 Kojo Tanaka Collapsible water-containing capsules
US20110023187A1 (en) * 2007-02-05 2011-01-27 National University Of Singapore Putative Cytokinin Receptor and Methods for Use Thereof
US20110184036A1 (en) * 2010-01-28 2011-07-28 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20120288546A1 (en) * 2009-12-29 2012-11-15 Demetrius Michos Compositions for Forming Films Having a Desired Degree of Obscuration and Methods of Making and Using the Same
US20120311734A1 (en) * 2011-06-04 2012-12-06 The Texas A&M University System Potato transformation compositions, systems, methods, microorganisms, and plants
US20130022565A1 (en) * 2010-04-02 2013-01-24 L'oreal Bleaching composition comprising a peroxygenated salt in a base very rich in fatty substances
US20130079419A1 (en) * 2010-05-07 2013-03-28 Qiqing Zhang High solvent content emulsions
US20130171237A1 (en) * 2010-10-28 2013-07-04 Fotios M. Plakogiannis Aripiprazole compositions and methods for its transdermal delivery
US20130243703A1 (en) * 2010-02-04 2013-09-19 Ashland Licensing And Intellectual Property Llc Self adapting polymers for anhydrous sunscreen formulations
WO2013142358A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20140106434A1 (en) * 2012-10-11 2014-04-17 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase production in tobacco leaves
US20140182013A1 (en) * 2012-12-20 2014-06-26 Ut Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in populus, gene y
US20140196175A1 (en) * 2010-02-18 2014-07-10 Athenix Corp. AXMI221z, AXMI222z, AXMI223z, AXMI224z and AXMI225z DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE
US20140215655A1 (en) * 2011-08-12 2014-07-31 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
US20140245491A1 (en) * 2010-02-18 2014-08-28 Athenix Corp. Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230 and axmi231 delta-endotoxin genes and methods for their use
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
US20140352000A1 (en) * 2010-08-19 2014-11-27 Pioneer Hi Bred International Inc Novel bacillus thuringiensis gene with lepidopteran activity
US20140370180A1 (en) * 2011-10-05 2014-12-18 Fmc Corporation Stabilizer Composition of Microcrystalline Cellulose and Carboxymethylcellulose, Method for Making, and Uses
US9000021B2 (en) 2012-03-20 2015-04-07 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US20150119248A1 (en) * 2010-06-04 2015-04-30 Monsanto Technology Llc Transgenic brassica event mon 88302 and methods of use thereof
US20150209482A1 (en) * 2004-09-28 2015-07-30 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20150306228A1 (en) * 2004-04-13 2015-10-29 Alexander K. Andrianov Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents
US20150327545A1 (en) * 2013-03-15 2015-11-19 Maria Beug-Deeb Inc. Dba T&M Associates Methods and compositions for cleaning and disinfecting surfaces
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
US20160032115A1 (en) * 2013-03-08 2016-02-04 Tbf Environmental Technology Inc. Solvent formulations
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
US20160074549A1 (en) * 2014-09-17 2016-03-17 Lonza, Inc. Activated disinfectant hydrogen peroxide compositions
US20160106680A1 (en) * 2013-05-31 2016-04-21 Pharmascience Inc. Abuse Deterrent Immediate Release Formulation
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US9422557B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9422558B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9540642B2 (en) 2013-11-04 2017-01-10 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods for controlling arthropod parasite and pest infestations
US9585937B2 (en) * 2011-12-07 2017-03-07 Msm Innovations, Inc. Method and kit for bowel preparation
US9603930B2 (en) * 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
US20170172975A1 (en) * 2009-04-10 2017-06-22 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
US9777288B2 (en) 2013-07-19 2017-10-03 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US9808421B2 (en) 2010-11-01 2017-11-07 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US20180008520A1 (en) * 2016-07-08 2018-01-11 The Gillette Company Llc Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
WO2018045136A1 (en) 2016-08-31 2018-03-08 Navinta, Llc Bendamustine solution formulations
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US20180078493A1 (en) * 2012-01-27 2018-03-22 Agile Therapeutics, Inc. Transdermal hormone delivery
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9962396B2 (en) 2009-05-04 2018-05-08 Psivida Us, Inc. Porous silicon drug-eluting particles
US20180140551A1 (en) * 2015-04-16 2018-05-24 Kate Somerville Skincare, LLC Self-foaming compositions and methods
US9980911B2 (en) 2013-03-15 2018-05-29 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
US9988634B2 (en) 2010-03-08 2018-06-05 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041068B2 (en) 2013-01-01 2018-08-07 A. B. Seeds Ltd. Isolated dsRNA molecules and methods of using same for silencing target molecules of interest
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10077451B2 (en) 2012-10-18 2018-09-18 Monsanto Technology Llc Methods and compositions for plant pest control
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10238603B2 (en) * 2014-09-11 2019-03-26 Gelita Ag Gelatin/pectin particles
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10251826B2 (en) * 2016-11-24 2019-04-09 Henkel Ag & Co. Kgaa Alkaline agent for lightening hair containing oxidants and special carboxylic acid esters
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10307443B2 (en) 2014-07-08 2019-06-04 Mimedx Group, Inc. Micronized wharton's jelly
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10334848B2 (en) 2014-01-15 2019-07-02 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10435701B2 (en) 2013-03-14 2019-10-08 Monsanto Technology Llc Methods and compositions for plant pest control
US10471096B2 (en) * 2015-01-06 2019-11-12 Osamu Yamada Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10557138B2 (en) 2013-12-10 2020-02-11 Beeologics, Inc. Compositions and methods for virus control in Varroa mite and bees
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US10609930B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10640735B2 (en) 2015-07-10 2020-05-05 The Procter & Gamble Company Fabric care composition comprising metathesized unsaturated polyol esters
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10772995B2 (en) 2004-09-28 2020-09-15 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10801028B2 (en) 2009-10-14 2020-10-13 Beeologics Inc. Compositions for controlling Varroa mites in bees
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10808249B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US10864304B2 (en) 2009-08-11 2020-12-15 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10869902B2 (en) 2004-09-28 2020-12-22 Atrium Medical Corporation Cured gel and method of making
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
US10888579B2 (en) 2007-11-07 2021-01-12 Beeologics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11083823B2 (en) 2005-09-28 2021-08-10 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
US11097035B2 (en) 2010-07-16 2021-08-24 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US11123298B2 (en) * 2017-03-01 2021-09-21 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11166929B2 (en) 2009-03-10 2021-11-09 Atrium Medical Corporation Fatty-acid based particles
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11492758B2 (en) 2015-02-25 2022-11-08 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11648188B1 (en) * 2012-01-16 2023-05-16 American Spraytech, L.L.C. Aerosol sprayable color composition
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
CN104224703A (en) 2008-09-25 2014-12-24 赛福伦公司 Liquid Formulations Of Bendamustine
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
EP2585060B1 (en) * 2010-06-21 2018-01-24 Peter MacCallum Cancer Institute Stimulating immune response
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
KR101978527B1 (en) 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. Stable formulations for parenteral injection of peptide drugs
JP2013032332A (en) * 2011-07-01 2013-02-14 Lintec Corp Immunoactivator
EP2758052B9 (en) * 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
CN104011029B (en) 2011-09-26 2016-06-08 费森尤斯卡比肿瘤学有限公司 A kind ofly prepare improving one's methods of bendamustine hydrochloride
EP2806872A1 (en) * 2012-01-24 2014-12-03 Innopharma, Inc. Bendamustine compositions and methods therefore
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013148919A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment of multiple myeloma
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9801859B2 (en) 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
TWI598341B (en) 2012-11-12 2017-09-11 伊格尼塔公司 Bendamustine derivatives and methods of using same
PL2732811T3 (en) * 2012-11-19 2016-05-31 Oncotec Pharma Produktion Gmbh Method for producing a freeze-dried compound
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CN103351347A (en) * 2013-07-29 2013-10-16 东南大学 Preparation method of impurity DCE in bendamustine hydrochloride
AU2014311570C1 (en) 2013-08-27 2018-08-02 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
WO2015054550A1 (en) * 2013-10-11 2015-04-16 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
WO2015104720A2 (en) * 2014-01-13 2015-07-16 Hetero Research Foundation Parenteral compositions of bendamustine
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN105726472B (en) * 2016-03-25 2019-12-13 南京康玻斯医药科技有限公司 bendamustine medicament composition and application thereof
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
BR112020006360A2 (en) 2017-10-05 2020-09-24 Tube Pharmaceuticals Gmbh composition for use as a medicament and oral pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable salt or solvate, use and method of delivery of bendamustine or a pharmaceutically acceptable salt or solvate, method of treating a disease or dysfunction in a subject in need of same
WO2019097413A1 (en) * 2017-11-15 2019-05-23 Intas Pharmaceuticals Ltd. Stable non-aqueous pharmaceutical compositions
EP3773498B1 (en) 2018-03-29 2022-06-22 Project Pharmaceutics GmbH Liquid pharmaceutical formulation
US20210275500A1 (en) * 2018-08-17 2021-09-09 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (en) * 2019-01-07 2023-03-08 コーアイセイ株式会社 Liquid formulations of bendamustine
CN110123747A (en) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 The preparation of bendamustine
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (en) 1903-10-08 1905-03-16
DD159289A1 (en) 1981-06-01 1983-03-02 Uwe Olthoff METHOD FOR PRODUCING STABLE INJECTION SOLUTIONS OF N-LOST COMPOUNDS
DD159877A1 (en) 1981-06-12 1983-04-13 Wolfgang Krueger PROCESS FOR PREPARING 4- [1-METHYL-5-BIS (2-CHLOROETHYL) AMINO-BENZIMIDAZOLYL-2] BUTTERIC ACID
IT1153974B (en) * 1982-09-23 1987-01-21 Erba Farmitalia PHARMACOLOGICAL COMPOSITIONS BASED ON CISPLATIN AND METHOD FOR THEIR OBTAINMENT
DE3446873A1 (en) * 1984-12-21 1986-07-10 Merckle Gmbh LIQUID DICLOFENAC PREPARATIONS
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5051257A (en) * 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (en) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De PROCESS FOR PREPARING (5- [BIS- (2-CHLOROETHYL) AMINO] -1-METHYL-BENZIMIDAZOLYL (2) ETHANEAN ACORESIS
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DE122004000036I1 (en) * 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0725642T3 (en) * 1993-10-27 2000-05-29 Upjohn Co Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (en) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamide lyophilizate preparations
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6573292B1 (en) * 1998-07-09 2003-06-03 Salmedix, Inc. Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (en) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Automated testing of activity of cell-modifying agents useful for selecting cytostatic agents for particular treatments
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0401811A2 (en) * 2000-12-11 2004-12-28 Takeda Chemical Industries, Ltd. Medicinal composition improved in solubility in water and process for its preparation
US20040053972A1 (en) * 2000-12-11 2004-03-18 Eiji Nara Medicinal compositions having improved absorbability
DE50213462D1 (en) * 2001-10-15 2009-05-28 Hemoteq Ag COATING OF STENTS TO PREVENT RESTENOSIS
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (en) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Liposomes, useful in compositions for the treatment of malignant diseases, especially non-Hodgkin lymphoma and chronic lymphatic leukemia, comprise a high bendamustine content,
CN100561229C (en) 2002-03-22 2009-11-18 克里斯蒂安·施特拉卡 Cytocapacity test
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
BR0310008A (en) * 2002-05-09 2005-02-15 Hemoteq Gmbh Preparation, method and use of hemocompatible coatings for the prevention of restenosis
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (en) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Process for the preparation of an oral dosage form with immediate disintegration and drug release
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) * 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
JP2007500191A (en) * 2003-07-25 2007-01-11 ワイス Freeze-dried formulation of CCI-779
CA2585659A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
UA94036C2 (en) * 2005-01-14 2011-04-11 Сефалон, Инк. Bendamustine pharmaceutical compositions for lyophilisation
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
AR072777A1 (en) * 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
CN104224703A (en) 2008-09-25 2014-12-24 赛福伦公司 Liquid Formulations Of Bendamustine

Cited By (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150306228A1 (en) * 2004-04-13 2015-10-29 Alexander K. Andrianov Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents
US20150209482A1 (en) * 2004-09-28 2015-07-30 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10814043B2 (en) 2004-09-28 2020-10-27 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US11793912B2 (en) 2004-09-28 2023-10-24 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10869902B2 (en) 2004-09-28 2020-12-22 Atrium Medical Corporation Cured gel and method of making
US9827352B2 (en) * 2004-09-28 2017-11-28 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US10772995B2 (en) 2004-09-28 2020-09-15 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US11083823B2 (en) 2005-09-28 2021-08-10 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20110023187A1 (en) * 2007-02-05 2011-01-27 National University Of Singapore Putative Cytokinin Receptor and Methods for Use Thereof
US9290777B2 (en) * 2007-02-05 2016-03-22 National University Of Singapore Putative cytokinin receptor and methods for use thereof
US10888579B2 (en) 2007-11-07 2021-01-12 Beeologics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US20100203096A1 (en) * 2009-02-06 2010-08-12 Kojo Tanaka Collapsible water-containing capsules
US11166929B2 (en) 2009-03-10 2021-11-09 Atrium Medical Corporation Fatty-acid based particles
US20170172975A1 (en) * 2009-04-10 2017-06-22 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
US9962396B2 (en) 2009-05-04 2018-05-08 Psivida Us, Inc. Porous silicon drug-eluting particles
US10864304B2 (en) 2009-08-11 2020-12-15 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10801028B2 (en) 2009-10-14 2020-10-13 Beeologics Inc. Compositions for controlling Varroa mites in bees
US11000711B2 (en) * 2009-12-29 2021-05-11 W. R. Grace & Co.-Conn. Compositions for forming films having a desired degree of obscuration and methods of making and using the same
US20120288546A1 (en) * 2009-12-29 2012-11-15 Demetrius Michos Compositions for Forming Films Having a Desired Degree of Obscuration and Methods of Making and Using the Same
US9265831B2 (en) 2010-01-28 2016-02-23 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10010533B2 (en) 2010-01-28 2018-07-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572797B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572796B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11872214B2 (en) 2010-01-28 2024-01-16 Eagle Pharmaceuticals, Inc. Formulations of Bendamustine
US8609707B2 (en) 2010-01-28 2013-12-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20110184036A1 (en) * 2010-01-28 2011-07-28 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11103483B2 (en) 2010-01-28 2021-08-31 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20130243703A1 (en) * 2010-02-04 2013-09-19 Ashland Licensing And Intellectual Property Llc Self adapting polymers for anhydrous sunscreen formulations
US10729625B2 (en) * 2010-02-04 2020-08-04 Isp Investments Llc Self adapting polymers for anhydrous sunscreen formulations
US10059960B2 (en) 2010-02-18 2018-08-28 Athenix Corp. AXMI221z, AXMI222z, AXMI223z, AXMI224z, and AXMI225z delta-endotoxin genes and methods for their use
US20140245491A1 (en) * 2010-02-18 2014-08-28 Athenix Corp. Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230 and axmi231 delta-endotoxin genes and methods for their use
US9156895B2 (en) * 2010-02-18 2015-10-13 Athenix Corp. AXMI218, AXMI219, AXMI220, AXMI226, AXMI227, AXMI228, AXMI229, AXMI230 and AXMI231 delta-endotoxin genes and methods for their use
US20140196175A1 (en) * 2010-02-18 2014-07-10 Athenix Corp. AXMI221z, AXMI222z, AXMI223z, AXMI224z and AXMI225z DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE
US9206249B2 (en) * 2010-02-18 2015-12-08 Athenix Corp. AXMI221z, AXMI222z, AXMI223z, AXMI224z and AXMI225z delta-endotoxin genes and methods for their use
US11812738B2 (en) 2010-03-08 2023-11-14 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US9988634B2 (en) 2010-03-08 2018-06-05 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US20130022565A1 (en) * 2010-04-02 2013-01-24 L'oreal Bleaching composition comprising a peroxygenated salt in a base very rich in fatty substances
US20130079419A1 (en) * 2010-05-07 2013-03-28 Qiqing Zhang High solvent content emulsions
US9539190B2 (en) 2010-05-07 2017-01-10 Conopco, Inc. Skin conditioning compositions containing 12-hydroxystearic acid
US20150119248A1 (en) * 2010-06-04 2015-04-30 Monsanto Technology Llc Transgenic brassica event mon 88302 and methods of use thereof
US9738903B2 (en) 2010-06-04 2017-08-22 Monsanto Technology Llc Transgenic brassica event MON 88302 and methods of use thereof
US11193137B2 (en) 2010-06-04 2021-12-07 Monsanto Technology Llc Late season application of glyphosate for weed control in Brassica
US11097035B2 (en) 2010-07-16 2021-08-24 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US20140352001A1 (en) * 2010-08-19 2014-11-27 Pioneer Hi Bred International Inc Novel bacillus thuringiensis gene with lepidopteran activity
US20140352000A1 (en) * 2010-08-19 2014-11-27 Pioneer Hi Bred International Inc Novel bacillus thuringiensis gene with lepidopteran activity
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
US20130171237A1 (en) * 2010-10-28 2013-07-04 Fotios M. Plakogiannis Aripiprazole compositions and methods for its transdermal delivery
US11026885B2 (en) 2010-11-01 2021-06-08 Eyepoint Pharmaceuticas, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US9808421B2 (en) 2010-11-01 2017-11-07 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US20120311734A1 (en) * 2011-06-04 2012-12-06 The Texas A&M University System Potato transformation compositions, systems, methods, microorganisms, and plants
US20140215655A1 (en) * 2011-08-12 2014-07-31 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US9422557B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US10435702B2 (en) 2011-09-13 2019-10-08 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10808249B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US9422558B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10428338B2 (en) 2011-09-14 2019-10-01 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US9826763B2 (en) * 2011-10-05 2017-11-28 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
US20140370180A1 (en) * 2011-10-05 2014-12-18 Fmc Corporation Stabilizer Composition of Microcrystalline Cellulose and Carboxymethylcellulose, Method for Making, and Uses
US9585937B2 (en) * 2011-12-07 2017-03-07 Msm Innovations, Inc. Method and kit for bowel preparation
US11648188B1 (en) * 2012-01-16 2023-05-16 American Spraytech, L.L.C. Aerosol sprayable color composition
US20180078493A1 (en) * 2012-01-27 2018-03-22 Agile Therapeutics, Inc. Transdermal hormone delivery
EP3533447A1 (en) 2012-03-20 2019-09-04 Eagle Pharmaceuticals, Inc. Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US9597397B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597398B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP4218756A1 (en) 2012-03-20 2023-08-02 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US9597399B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9000021B2 (en) 2012-03-20 2015-04-07 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US20230285563A1 (en) * 2012-03-20 2023-09-14 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572888B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572887B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9579384B2 (en) 2012-03-20 2017-02-28 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US9034908B2 (en) 2012-03-20 2015-05-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10052385B2 (en) 2012-03-20 2018-08-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013142358A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9144568B1 (en) 2012-03-20 2015-09-29 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10240162B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10934555B2 (en) 2012-05-24 2021-03-02 Monsanto Technology Llc Compositions and methods for silencing gene expression
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US11078522B2 (en) 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US20140106434A1 (en) * 2012-10-11 2014-04-17 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase production in tobacco leaves
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
US10844398B2 (en) 2012-10-18 2020-11-24 Monsanto Technology Llc Methods and compositions for plant pest control
US10077451B2 (en) 2012-10-18 2018-09-18 Monsanto Technology Llc Methods and compositions for plant pest control
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20140182013A1 (en) * 2012-12-20 2014-06-26 Ut Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in populus, gene y
US9206436B2 (en) * 2012-12-20 2015-12-08 Ut-Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
US10041068B2 (en) 2013-01-01 2018-08-07 A. B. Seeds Ltd. Isolated dsRNA molecules and methods of using same for silencing target molecules of interest
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US20160032115A1 (en) * 2013-03-08 2016-02-04 Tbf Environmental Technology Inc. Solvent formulations
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
US20160346211A1 (en) * 2013-03-12 2016-12-01 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
US10609930B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10435701B2 (en) 2013-03-14 2019-10-08 Monsanto Technology Llc Methods and compositions for plant pest control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9980911B2 (en) 2013-03-15 2018-05-29 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
US10426164B2 (en) * 2013-03-15 2019-10-01 Maria Beug-Deeb, inc. Methods and compositions for cleaning and disinfecting surfaces
US20150327545A1 (en) * 2013-03-15 2015-11-19 Maria Beug-Deeb Inc. Dba T&M Associates Methods and compositions for cleaning and disinfecting surfaces
US20160106680A1 (en) * 2013-05-31 2016-04-21 Pharmascience Inc. Abuse Deterrent Immediate Release Formulation
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US9856495B2 (en) * 2013-07-19 2018-01-02 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US11377667B2 (en) 2013-07-19 2022-07-05 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10597676B2 (en) 2013-07-19 2020-03-24 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US9777288B2 (en) 2013-07-19 2017-10-03 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
US10927374B2 (en) 2013-11-04 2021-02-23 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
US10100306B2 (en) 2013-11-04 2018-10-16 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
US9540642B2 (en) 2013-11-04 2017-01-10 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods for controlling arthropod parasite and pest infestations
US10557138B2 (en) 2013-12-10 2020-02-11 Beeologics, Inc. Compositions and methods for virus control in Varroa mite and bees
US10334848B2 (en) 2014-01-15 2019-07-02 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10137449B2 (en) 2014-04-10 2018-11-27 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10307443B2 (en) 2014-07-08 2019-06-04 Mimedx Group, Inc. Micronized wharton's jelly
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
US11124792B2 (en) 2014-07-29 2021-09-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10238603B2 (en) * 2014-09-11 2019-03-26 Gelita Ag Gelatin/pectin particles
US10646607B2 (en) * 2014-09-17 2020-05-12 Lonza, Inc. Activated disinfectant hydrogen peroxide compositions
US20160074549A1 (en) * 2014-09-17 2016-03-17 Lonza, Inc. Activated disinfectant hydrogen peroxide compositions
US11167054B2 (en) 2014-09-17 2021-11-09 Lonza, Llc Activated disinfectant hydrogen peroxide compositions
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US9603930B2 (en) * 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
US10471096B2 (en) * 2015-01-06 2019-11-12 Osamu Yamada Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
US11492758B2 (en) 2015-02-25 2022-11-08 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20180140551A1 (en) * 2015-04-16 2018-05-24 Kate Somerville Skincare, LLC Self-foaming compositions and methods
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
US10640735B2 (en) 2015-07-10 2020-05-05 The Procter & Gamble Company Fabric care composition comprising metathesized unsaturated polyol esters
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11304885B2 (en) 2016-07-08 2022-04-19 The Gillette Company Llc Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
US10821061B2 (en) * 2016-07-08 2020-11-03 The Gillette Company Llc Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
US20180008520A1 (en) * 2016-07-08 2018-01-11 The Gillette Company Llc Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
WO2018045136A1 (en) 2016-08-31 2018-03-08 Navinta, Llc Bendamustine solution formulations
US10251826B2 (en) * 2016-11-24 2019-04-09 Henkel Ag & Co. Kgaa Alkaline agent for lightening hair containing oxidants and special carboxylic acid esters
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11123298B2 (en) * 2017-03-01 2021-09-21 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US11826471B2 (en) 2017-03-01 2023-11-28 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing

Also Published As

Publication number Publication date
US20140128443A1 (en) 2014-05-08
AU2015207940A1 (en) 2015-08-20
US20210113530A1 (en) 2021-04-22
EP2326306A1 (en) 2011-06-01
WO2010036702A1 (en) 2010-04-01
HK1211462A1 (en) 2016-05-27
AU2009296734A1 (en) 2010-04-01
AU2016203246A1 (en) 2016-06-09
CN102164579B (en) 2014-10-15
US20140080881A1 (en) 2014-03-20
US8344006B2 (en) 2013-01-01
US20110190363A1 (en) 2011-08-04
CA2735899A1 (en) 2010-04-01
CN104224703A (en) 2014-12-24
CN102164579A (en) 2011-08-24
JP5670335B2 (en) 2015-02-18
AU2016247123A1 (en) 2016-11-03
AU2015207940B2 (en) 2016-11-10
US20150335750A1 (en) 2015-11-26
US20180125824A1 (en) 2018-05-10
US20120129904A1 (en) 2012-05-24
JP2012503666A (en) 2012-02-09
US20210008035A1 (en) 2021-01-14
AU2016203246B2 (en) 2017-09-21
AU2018202107A1 (en) 2018-04-19
US20140206733A1 (en) 2014-07-24
EP2889029A1 (en) 2015-07-01
AU2009296734B2 (en) 2016-02-18
MX2011002936A (en) 2011-04-11

Similar Documents

Publication Publication Date Title
US20210113530A1 (en) Liquid formulations of bendamustine
US9572888B2 (en) Formulations of bendamustine
US9603930B2 (en) Liquid bendamustine formulation
US10905677B2 (en) Bendamustine solution formulations
US20190151234A1 (en) Stable liquid pharmaceutical formulations of bendamustine
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
US20150087681A1 (en) Bendamustine HCL Stable Lyophilized Formulations
US11826466B2 (en) Bendamustine solution formulations
US20140275122A1 (en) Voriconazole Formulations
US20190275102A1 (en) Sterile injectable composition comprising carfilzomib
WO2014170769A2 (en) Bendamustine lyophilized pharmaceutical compositions
US20190274986A1 (en) Sterile injectable composition comprising melphalan

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION